ClinicalTrials.gg
CompletedNCT03914755Updated Sep 6, 2019

A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects

A Phase 1 interventional study of Tucatinib in Healthy, sponsored by Seagen Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of tucatinib in healthy Japanese and Caucasian participants.

Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with and without food.

Subjects will be in the study for up to 45 days, including the screening period.

Due to practical considerations, each cohort will be dosed sequentially (this is not a dose escalation study).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 32 kg/m\^2 and a total body weight between 50 and 100 kg
  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, or clinical laboratory evaluations
  • Female subjects participating in the study will be of non-. Male subjects will be surgically sterile for at least 90 days or will agree to use during the study and for 90 days after last dose of study drug.
  • Japanese subjects:

    1. Must have been born in Japan
    2. Must have 2 biological Japanese parents and 4 biological Japanese grandparents as confirmed by interview
    3. Must have spent less than 10 years outside of Japan, and has no significant changes in lifestyle, including diet, since leaving Japan

Exclusion criteria

Exclusion Criteria:

  • Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
  • Current condition possibly affecting drug absorption
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs
  • History of alcoholism or drug/chemical abuse within 2 years of check-in
  • History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects
  • Positive hepatitis panel and/or positive human immunodeficiency () test
  • Liver function tests, serum creatinine, , or hematocrit values outside of the normal reference range
  • Single 12-lead demonstrating >450 msec for males or >470 msec for females
  • Participation in a clinical study involving administration of an drug in the past 30 days from last dose or 5 half-lives (whichever is longer)
  • Use of any products known to alter drug absorption, metabolism or elimination processes, including St. John's wort and known strong inhibitors or inducers of or CYP2C8, within 30 days
  • Use of or intention to use any prescription or nonprescription products, including vitamins, minerals and herbal preparations within 14 days
  • Use of tobacco- or nicotine-containing products within 3 months
  • Receipt of blood products within 2 months
  • Donation of blood from 56 days before the Screening Visit, plasma from 2 weeks before the Screening Visit or from 6 weeks before the Screening Visit
  • Poor peripheral venous access
  • Have previously completed or withdrawn from this study or any other study investigating tucatinib and have previously received the study drug
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    50 mg twice daily on Days 1-13 and once daily on Day 14

    Drug: Tucatinib

  • Experimental
    Cohort 2

    150 mg twice daily on Days 1-13 and once daily on Day 14

    Drug: Tucatinib

  • Experimental
    Cohort 3

    300 mg twice daily on Days 1-13 and once daily on Day 14

    Drug: Tucatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) of tucatinib

    Time frame: 14 days

  2. Cmax of ONT-993

    Time frame: 14 days

  3. Time of the maximum observed concentration (tmax) of tucatinib

    Time frame: 14 days

  4. Tmax of ONT-993

    Time frame: 14 days

  5. AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib

    Time frame: 14 days

  6. AUClast of ONT-993

    Time frame: 14 days

  7. AUC from time 0 to 12 hours postdose (AUC0-12hr) of tucatinib

    Time frame: 14 days

  8. AUC0-12hr of ONT-993

    Time frame: 14 days

  9. AUC from time 0 extrapolated to infinity (AUC0-inf) of tucatinib

    Time frame: 1 day

  10. AUC from time 0 extrapolated to infinity (AUC0-inf) of ONT-993

    Time frame: 1 day

  11. Percentage of AUC0-inf due to extrapolation (%AUCextrap) of tucatinib

    Time frame: 1 day

  12. %AUCextrap of ONT-993

    Time frame: 1 day

  13. Apparent total clearance (CL/F) of tucatinib

    Time frame: 14 days

  14. Apparent volume of distribution during the terminal phase (Vz/F) of tucatinib

    Time frame: 14 days

  15. Metabolite-to-parent molar ratio based on AUC (MRAUC) of ONT-993

    Time frame: 14 days

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: 17 days

07

Study locations

1 site
  • PAREXEL International, Early Phase Clinical Unit - Los Angeles
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Aug 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
Apr 16, 2019
StartActual
May 8, 2019
Primary completionActual
Aug 4, 2019
CompletionActual
Aug 4, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03914755
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
May 8, 2019
Primary completion
Aug 4, 2019
Completion
Aug 4, 2019
Last update
Sep 6, 2019

Study contacts

Joseph Woolery, PharmD, BCOP
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion